Papers/PMID:41800295
Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study.
Drug design, development and therapy2026The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
coenzyme Q10 — no detected effect on clinical pregnancy rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“No noticeable variations were demonstrated in clinical pregnancy rates (P = 0.888), lower miscarriage rates (p = 0.676), or twin pregnancies (p = 0.792); however, CoQ10 appeared to demonstrate promising outcomes (Table 3).”
Quoted verbatim from Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study.. - Study
- RCT
- Dose
- Coenzyme Q10 200 mg twice daily (Synapse CoQ10 200 mg, Synapse Pharm), started one month before the ICSI cycle and continued through it
- Population
- Women aged 25 to 45 with poor ovarian response by the Bologna criteria undergoing intracytoplasmic sperm injection; secondary endpoint.
Coenzyme Q10 Impact on Ovarian Reserve Measures and the Intra-Cytoplasmic Sperm Injection (ICSI) Outcomes in Women with Poor Ovarian Response: A Randomized Controlled Study.2026PMID:41800295Permalink